Desmopressin  ||| S:0 E:13 ||| JJ
parenteral  ||| S:13 E:24 ||| NN
in  ||| S:24 E:27 ||| IN
patients  ||| S:27 E:36 ||| NNS
with  ||| S:36 E:41 ||| IN
VWD1 ||| S:41 E:45 ||| NNP
,  ||| S:45 E:47 ||| ,
VWD  ||| S:47 E:51 ||| NNP
2A  ||| S:51 E:54 ||| NNP
and  ||| S:54 E:58 ||| CC
thrombocytopathy  ||| S:58 E:75 ||| JJ
Desmopressin  ||| S:75 E:88 ||| NNP
( ||| S:88 E:89 ||| -LRB-
DDAVP ||| S:89 E:94 ||| NNP
,  ||| S:94 E:96 ||| ,
Minirin®  ||| S:96 E:105 ||| CD
parenteral ||| S:105 E:115 ||| CD
) ||| S:115 E:116 ||| -RRB-
,  ||| S:116 E:118 ||| ,
which  ||| S:118 E:124 ||| WDT
induces  ||| S:124 E:132 ||| VBZ
the  ||| S:132 E:136 ||| DT
release  ||| S:136 E:144 ||| NN
of  ||| S:144 E:147 ||| IN
von-Willebrand  ||| S:147 E:162 ||| JJ
factor  ||| S:162 E:169 ||| NN
from  ||| S:169 E:174 ||| IN
endogenous  ||| S:174 E:185 ||| JJ
stores ||| S:185 E:191 ||| NNS
,  ||| S:191 E:193 ||| ,
is  ||| S:193 E:196 ||| VBZ
indicated  ||| S:196 E:206 ||| VBN
in  ||| S:206 E:209 ||| IN
von  ||| S:209 E:213 ||| NNP
Willebrand  ||| S:213 E:224 ||| NNP
disease  ||| S:224 E:232 ||| NN
type  ||| S:232 E:237 ||| NN
1  ||| S:237 E:239 ||| CD
( ||| S:239 E:240 ||| -LRB-
VWD  ||| S:240 E:244 ||| NNP
1 ||| S:244 E:245 ||| CD
) ||| S:245 E:246 ||| -RRB-
.  ||| S:246 E:248 ||| .
In  ||| S:248 E:251 ||| IN
the  ||| S:251 E:255 ||| DT
present  ||| S:255 E:263 ||| JJ
study  ||| S:263 E:269 ||| NN
effectiveness  ||| S:269 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
DDAVP  ||| S:286 E:292 ||| NNP
was  ||| S:292 E:296 ||| VBD
tested  ||| S:296 E:303 ||| VBN
and  ||| S:303 E:307 ||| CC
side  ||| S:307 E:312 ||| NN
effects  ||| S:312 E:320 ||| NNS
were  ||| S:320 E:325 ||| VBD
recorded  ||| S:325 E:334 ||| VBN
in  ||| S:334 E:337 ||| IN
patients  ||| S:337 E:346 ||| NNS
with  ||| S:346 E:351 ||| IN
VWD  ||| S:351 E:355 ||| NNP
1 ||| S:355 E:356 ||| CD
,  ||| S:356 E:358 ||| ,
von  ||| S:358 E:362 ||| NNP
Willebrand  ||| S:362 E:373 ||| NNP
disease  ||| S:373 E:381 ||| NN
type  ||| S:381 E:386 ||| NN
2  ||| S:386 E:388 ||| CD
( ||| S:388 E:389 ||| -LRB-
VWD  ||| S:389 E:393 ||| NNP
2 ||| S:393 E:394 ||| CD
)  ||| S:394 E:396 ||| -RRB-
or  ||| S:396 E:399 ||| CC
thrombocytopathy  ||| S:399 E:416 ||| NNS
( ||| S:416 E:417 ||| -LRB-
TCP ||| S:417 E:420 ||| NNP
) ||| S:420 E:421 ||| -RRB-
.  ||| S:421 E:423 ||| .
Subjects  ||| S:423 E:432 ||| NNS
were  ||| S:432 E:437 ||| VBD
analysed  ||| S:437 E:446 ||| VBN
prior  ||| S:446 E:452 ||| RB
to  ||| S:452 E:455 ||| TO
and  ||| S:455 E:459 ||| CC
after  ||| S:459 E:465 ||| IN
Minirin  ||| S:465 E:473 ||| NNP
parenteral  ||| S:473 E:484 ||| FW
infusion  ||| S:484 E:493 ||| FW
( ||| S:493 E:494 ||| -LRB-
0.4  ||| S:494 E:498 ||| CD
μg ||| S:498 E:500 ||| CD
/ ||| S:500 E:501 ||| CD
kg  ||| S:501 E:504 ||| JJ
body  ||| S:504 E:509 ||| NN
weight  ||| S:509 E:516 ||| NN
( ||| S:516 E:517 ||| -LRB-
b.w. ||| S:517 E:521 ||| NNP
)  ||| S:521 E:523 ||| -RRB-
over  ||| S:523 E:528 ||| IN
60  ||| S:528 E:531 ||| CD
minutes ||| S:531 E:538 ||| NNS
)  ||| S:538 E:540 ||| -RRB-
for  ||| S:540 E:544 ||| IN
partial  ||| S:544 E:552 ||| JJ
thromboplastin  ||| S:552 E:567 ||| JJ
time  ||| S:567 E:572 ||| NN
( ||| S:572 E:573 ||| -LRB-
PTT ||| S:573 E:576 ||| NNP
,  ||| S:576 E:578 ||| ,
seconds ||| S:578 E:585 ||| NNS
) ||| S:585 E:586 ||| -RRB-
,  ||| S:586 E:588 ||| ,
ADP ||| S:588 E:591 ||| FW
/ ||| S:591 E:592 ||| FW
epinephrine  ||| S:592 E:604 ||| FW
triggered  ||| S:604 E:614 ||| FW
platelet-function  ||| S:614 E:632 ||| FW
analyzer  ||| S:632 E:641 ||| FW
( ||| S:641 E:642 ||| -LRB-
PFA-100 ||| S:642 E:649 ||| NNP
)  ||| S:649 E:651 ||| -RRB-
occlusion  ||| S:651 E:661 ||| JJ
time  ||| S:661 E:666 ||| NN
( ||| S:666 E:667 ||| -LRB-
seconds ||| S:667 E:674 ||| NNS
) ||| S:674 E:675 ||| -RRB-
,  ||| S:675 E:677 ||| ,
factor  ||| S:677 E:684 ||| NN
VIII  ||| S:684 E:689 ||| NNP
activity  ||| S:689 E:698 ||| NN
( ||| S:698 E:699 ||| -LRB-
FVIII ||| S:699 E:704 ||| NNP
,  ||| S:704 E:706 ||| ,
% ||| S:706 E:707 ||| NN
) ||| S:707 E:708 ||| -RRB-
,  ||| S:708 E:710 ||| ,
VWF  ||| S:710 E:714 ||| NNP
as  ||| S:714 E:717 ||| IN
ristocetin  ||| S:717 E:728 ||| JJ
cofactor  ||| S:728 E:737 ||| JJ
activity  ||| S:737 E:746 ||| NN
( ||| S:746 E:747 ||| -LRB-
VWF ||| S:747 E:750 ||| NNP
: ||| S:750 E:751 ||| :
RCo ||| S:751 E:754 ||| NNP
,  ||| S:754 E:756 ||| ,
% ||| S:756 E:757 ||| NN
)  ||| S:757 E:759 ||| -RRB-
and  ||| S:759 E:763 ||| CC
VWF  ||| S:763 E:767 ||| NNP
antigen  ||| S:767 E:775 ||| NN
( ||| S:775 E:776 ||| -LRB-
VWF ||| S:776 E:779 ||| NNP
: ||| S:779 E:780 ||| :
Ag ||| S:780 E:782 ||| NNP
,  ||| S:782 E:784 ||| ,
% ||| S:784 E:785 ||| NN
) ||| S:785 E:786 ||| -RRB-
.  ||| S:786 E:788 ||| .
Side  ||| S:788 E:793 ||| NN
effects  ||| S:793 E:801 ||| NNS
of  ||| S:801 E:804 ||| IN
DDAVP  ||| S:804 E:810 ||| NNP
during  ||| S:810 E:817 ||| IN
operative  ||| S:817 E:827 ||| JJ
interventions  ||| S:827 E:841 ||| NNS
were  ||| S:841 E:846 ||| VBD
recorded  ||| S:846 E:855 ||| VBN
per  ||| S:855 E:859 ||| IN
questionnaires  ||| S:859 E:874 ||| NN
by  ||| S:874 E:877 ||| IN
the  ||| S:877 E:881 ||| DT
patients ||| S:881 E:889 ||| NNS
.  ||| S:889 E:891 ||| .
The  ||| S:891 E:895 ||| DT
mean  ||| S:895 E:900 ||| JJ
±  ||| S:900 E:902 ||| CD
standard  ||| S:902 E:911 ||| JJ
deviation  ||| S:911 E:921 ||| NN
dose  ||| S:921 E:926 ||| NN
( ||| S:926 E:927 ||| -LRB-
n  ||| S:927 E:929 ||| CD
=  ||| S:929 E:931 ||| SYM
165  ||| S:931 E:935 ||| CD
patients ||| S:935 E:943 ||| NNS
)  ||| S:943 E:945 ||| -RRB-
of  ||| S:945 E:948 ||| IN
Minirin  ||| S:948 E:956 ||| NNP
parenteral  ||| S:956 E:967 ||| NN
administered  ||| S:967 E:980 ||| NNS
was  ||| S:980 E:984 ||| VBD
0.37  ||| S:984 E:989 ||| CD
±  ||| S:989 E:991 ||| CD
0.02  ||| S:991 E:996 ||| CD
μg ||| S:996 E:998 ||| CD
/ ||| S:998 E:999 ||| CD
kg  ||| S:999 E:1002 ||| CD
b.w. ||| S:1002 E:1006 ||| CD
,  ||| S:1006 E:1008 ||| ,
most  ||| S:1008 E:1013 ||| RBS
often  ||| S:1013 E:1019 ||| RB
upcoming  ||| S:1019 E:1028 ||| JJ
dental  ||| S:1028 E:1035 ||| JJ
operations  ||| S:1035 E:1046 ||| NNS
( ||| S:1046 E:1047 ||| -LRB-
57 ||| S:1047 E:1049 ||| CD
% ||| S:1049 E:1050 ||| NN
)  ||| S:1050 E:1052 ||| -RRB-
necessitated  ||| S:1052 E:1065 ||| JJ
testing ||| S:1065 E:1072 ||| NN
.  ||| S:1072 E:1074 ||| .
Coagulation  ||| S:1074 E:1086 ||| JJ
parameters  ||| S:1086 E:1097 ||| NNS
of  ||| S:1097 E:1100 ||| IN
patients  ||| S:1100 E:1109 ||| NNS
with  ||| S:1109 E:1114 ||| IN
VWD  ||| S:1114 E:1118 ||| NNP
1  ||| S:1118 E:1120 ||| CD
or  ||| S:1120 E:1123 ||| CC
TCP  ||| S:1123 E:1127 ||| NNP
normalised  ||| S:1127 E:1138 ||| NN
in  ||| S:1138 E:1141 ||| IN
almost  ||| S:1141 E:1148 ||| RB
all  ||| S:1148 E:1152 ||| DT
patients ||| S:1152 E:1160 ||| NNS
,  ||| S:1160 E:1162 ||| ,
but  ||| S:1162 E:1166 ||| CC
only  ||| S:1166 E:1171 ||| RB
in  ||| S:1171 E:1174 ||| IN
approximately  ||| S:1174 E:1188 ||| RB
50 ||| S:1188 E:1190 ||| CD
%  ||| S:1190 E:1192 ||| NN
of  ||| S:1192 E:1195 ||| IN
patients  ||| S:1195 E:1204 ||| NNS
with  ||| S:1204 E:1209 ||| IN
VWD  ||| S:1209 E:1213 ||| NNP
2  ||| S:1213 E:1215 ||| CD
respectively ||| S:1215 E:1227 ||| RB
.  ||| S:1227 E:1229 ||| .
Appraisal  ||| S:1229 E:1239 ||| NN
of  ||| S:1239 E:1242 ||| IN
effectiveness  ||| S:1242 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
Minirin  ||| S:1259 E:1267 ||| NNP
parenteral  ||| S:1267 E:1278 ||| NN
as  ||| S:1278 E:1281 ||| IN
good  ||| S:1281 E:1286 ||| JJ
was  ||| S:1286 E:1290 ||| VBD
96 ||| S:1290 E:1292 ||| CD
%  ||| S:1292 E:1294 ||| NN
in  ||| S:1294 E:1297 ||| IN
case  ||| S:1297 E:1302 ||| NN
of  ||| S:1302 E:1305 ||| IN
VWD  ||| S:1305 E:1309 ||| NNP
1  ||| S:1309 E:1311 ||| CD
and  ||| S:1311 E:1315 ||| CC
95  ||| S:1315 E:1318 ||| CD
%  ||| S:1318 E:1320 ||| NN
in  ||| S:1320 E:1323 ||| IN
case  ||| S:1323 E:1328 ||| NN
of  ||| S:1328 E:1331 ||| IN
TCP ||| S:1331 E:1334 ||| NNP
.  ||| S:1334 E:1336 ||| .
During  ||| S:1336 E:1343 ||| IN
minor  ||| S:1343 E:1349 ||| JJ
surgeries  ||| S:1349 E:1359 ||| NNS
( ||| S:1359 E:1360 ||| -LRB-
n  ||| S:1360 E:1362 ||| CD
=  ||| S:1362 E:1364 ||| SYM
23 ||| S:1364 E:1366 ||| CD
)  ||| S:1366 E:1368 ||| -RRB-
in  ||| S:1368 E:1371 ||| IN
91 ||| S:1371 E:1373 ||| CD
%  ||| S:1373 E:1375 ||| NN
of  ||| S:1375 E:1378 ||| IN
the  ||| S:1378 E:1382 ||| DT
patients  ||| S:1382 E:1391 ||| NNS
no  ||| S:1391 E:1394 ||| DT
complications  ||| S:1394 E:1408 ||| NNS
and  ||| S:1408 E:1412 ||| CC
in  ||| S:1412 E:1415 ||| IN
2  ||| S:1415 E:1417 ||| CD
patients  ||| S:1417 E:1426 ||| NNS
( ||| S:1426 E:1427 ||| -LRB-
9 ||| S:1427 E:1428 ||| CD
% ||| S:1428 E:1429 ||| NN
)  ||| S:1429 E:1431 ||| -RRB-
postoperative  ||| S:1431 E:1445 ||| JJ
haemorrhages  ||| S:1445 E:1458 ||| NN
without  ||| S:1458 E:1466 ||| IN
need  ||| S:1466 E:1471 ||| NN
for  ||| S:1471 E:1475 ||| IN
further  ||| S:1475 E:1483 ||| JJ
interventions  ||| S:1483 E:1497 ||| NNS
occurred ||| S:1497 E:1505 ||| VBD
,  ||| S:1505 E:1507 ||| ,
but  ||| S:1507 E:1511 ||| CC
83 ||| S:1511 E:1513 ||| CD
%  ||| S:1513 E:1515 ||| NN
of  ||| S:1515 E:1518 ||| IN
the  ||| S:1518 E:1522 ||| DT
patients  ||| S:1522 E:1531 ||| NNS
reported  ||| S:1531 E:1540 ||| VBD
adverse  ||| S:1540 E:1548 ||| JJ
reactions  ||| S:1548 E:1558 ||| NNS
in  ||| S:1558 E:1561 ||| IN
the  ||| S:1561 E:1565 ||| DT
questionnaires ||| S:1565 E:1579 ||| NN
,  ||| S:1579 E:1581 ||| ,
although  ||| S:1581 E:1590 ||| IN
Minirin  ||| S:1590 E:1598 ||| NNP
parenteral  ||| S:1598 E:1609 ||| NN
was  ||| S:1609 E:1613 ||| VBD
well  ||| S:1613 E:1618 ||| RB
tolerated  ||| S:1618 E:1628 ||| VBN
by  ||| S:1628 E:1631 ||| IN
all  ||| S:1631 E:1635 ||| DT
patients  ||| S:1635 E:1644 ||| NNS
during  ||| S:1644 E:1651 ||| IN
DDAVP  ||| S:1651 E:1657 ||| NNP
efficacy  ||| S:1657 E:1666 ||| NN
tests ||| S:1666 E:1671 ||| NNS
.  ||| S:1671 E:1673 ||| .
Desmopressin  ||| S:1673 E:1686 ||| NNP
is  ||| S:1686 E:1689 ||| VBZ
well  ||| S:1689 E:1694 ||| RB
tolerated  ||| S:1694 E:1704 ||| JJ
and  ||| S:1704 E:1708 ||| CC
affective  ||| S:1708 E:1718 ||| NN
in  ||| S:1718 E:1721 ||| IN
patients  ||| S:1721 E:1730 ||| NNS
with  ||| S:1730 E:1735 ||| IN
VWD  ||| S:1735 E:1739 ||| NNP
1  ||| S:1739 E:1741 ||| CD
and  ||| S:1741 E:1745 ||| CC
thrombocytopathy ||| S:1745 E:1761 ||| NN
.  ||| S:1761 E:1763 ||| .
